Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | ACR | P10323 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12742904 | 0.96 | KMT2A (0.44) | KMT2AMEN1ATMTHRBMAPT | |
| SCHEMBL16449833 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL16449870 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL16449879 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL742922 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL11917937 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL16449835 | 0.93 | THRB (0.46) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL12723906 | 0.92 | THRB (0.45) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL17734099 | 0.92 | THRB (0.45) | KMT2ATHRBMAPTPARP10HSD17B10 | |
| SCHEMBL12733799 | 0.92 | THRB (0.45) | KMT2ATHRBMAPTPARP10HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919009-B2 | Polymerizable compounds and polymerizable compositions | ADEKA CORPORATION (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7910021-B2 | Polymerizable optical active compound and polymerizable composition containing the same | ADEKA CORPORATION (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100032620-A1 | POLYMERIZABLE OPTICAL ACTIVE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100032621-A1 | POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS | ADEKA CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7449223-B2 | containing an additive that improves the level of defects in the vicinity of the air interface for an optically anisotropic medium that exhibits either tilted alignment or horizontal alignment | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20070170394-A1 | Polymerizable liquid crystal composition and optically anisotropic medium | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032620-A1 | POLYMERIZABLE OPTICAL ACTIVE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE SAME | C1S, PYM1, MCCC2 | KMT2A 3291/4885MEN1 360/4885ATM 1048/4885 |
| US-20100032621-A1 | POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS | CHRM1, CHRM2, CCNE1 | KMT2A 2784/4885MEN1 95/4885ATM 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.